Menu
1 min read · estimated
APPROVED USE
What FDA approved
First-line monotherapy for advanced non-small cell lung cancer with PD-L1 tumor proportion score of at least 50% by an FDA-approved test and without EGFR, ALK or ROS1 aberrations. This covers metastatic disease or locally advanced disease unsuitable for surgery or definitive chemoradiation.
LAMPGEN ANALYSIS
Why it matters
The original lung cancer indication is PD-L1-selected checkpoint monotherapy.
What research teams should watch
Retain the PD-L1 score, driver testing and confirmation of eligibility for definitive local therapy.
PRIMARY RECORDS